Long-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema.
Reference facts
- Also known as
- AM833
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Long-acting amylin and calcitonin receptor agonist. Slows gastric emptying and signals satiety via the area postrema.
- Targets
- AMY1R, AMY3R, Calcitonin receptor
- Indications under research or approved
- Obesity (in combination with Semaglutide as CagriSema)
- Regulatory status (reference entry)
- Investigational (Phase 3 REDEFINE)
- Half-life
- ~7 days
- Sequence
- KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY
- Sequence notes
- 37-residue long-acting amylin analog with C18 fatty diacid linker; lysine substitutions and disulfide between Cys2-Cys7.
- Molecular weight (Da)
- 3800
- Originator / sponsor
- Novo Nordisk
- First reported
- 2018
Primary References
Explore research articles about Cagrilintide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.